©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 203-209
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.203
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.203
Faecal calprotectin: Management in inflammatory bowel disease
José Manuel Benítez, Valle García-Sánchez, Department of Gastroenterology, University Hospital Reina Sofia (Córdoba), 14004 Córdoba, Spain
Author contributions: Benítez JM and García-Sánchez V contributed equally to this work.
Conflict-of-interest statement: The authors declare no have conflict of interest.
Correspondence to: José Manuel Benítez, MD, Department of Gastroenterology, University Hospital Reina Sofia (Córdoba), Avda.Menéndez Pidal s/n, 14004 Córdoba, Spain. jmbeni83@hotmail.com
Telephone: +34-95-7010450 Fax: +34-95-7012818
Received: June 30, 2015
Peer-review started: July 5, 2015
First decision: July 31, 2015
Revised: September 11, 2015
Accepted: October 23, 2015
Article in press: October 27, 2015
Published online: November 15, 2015
Processing time: 140 Days and 6 Hours
Peer-review started: July 5, 2015
First decision: July 31, 2015
Revised: September 11, 2015
Accepted: October 23, 2015
Article in press: October 27, 2015
Published online: November 15, 2015
Processing time: 140 Days and 6 Hours
Core Tip
Core tip: The surveillance of inflammatory bowel disease (IBD) course is needed to select the patients with worse prognosis and to adapt an early therapeutic strategy. Faecal calprotectin constitutes a surrogate marker of intestinal inflammation and a robust alternative to invasive procedures as endoscopy. This biomarker has been demonstrated reliable and accuracy in different aspects of IBD such as diagnosis of IBD, activity assessment, response to treatment and relapse prediction. Although a cut-off level of calprotectin has not been fully established, the combination with other biomarkers allows an appropriate management of the patient.